Rituximab treatment in ANCA-associated vasculitis patients: outcomes of a real-life experience from an observational cohort

Rituximab is a first-line therapy in patients with anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). Among previous studies evaluating its efficacy, the Hispanic/Latino population has been underrepresented. This study aimed to assess the outcomes of AAV patients treated with r...

Descripción completa

Detalles Bibliográficos
Autores principales: Carranza-Enríquez, Fabián, Meade-Aguilar, José Antonio, Hinojosa-Azaola, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065666/
https://www.ncbi.nlm.nih.gov/pubmed/35507201
http://dx.doi.org/10.1007/s10067-022-06192-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065666/
https://www.ncbi.nlm.nih.gov/pubmed/35507201
http://dx.doi.org/10.1007/s10067-022-06192-1

Ejemplares similares